Using pharmacogenetics to improve drug safety and efficacy

JAMA

Volumn 291, Issue 23, 2004, Pages 2869-2871

  Haga, Susanne B ^a   Burke, Wylie ^b  

^a Ctr for the Advancement of Genomics   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MERCAPTOPURINE; PRAVASTATIN; TIOGUANINE; TRIACYLGLYCEROL;

COMPETITIVE INHIBITION; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GENE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEALTH CARE COST; HMGCR GENE; HUMAN; HYPERCHOLESTEROLEMIA; NOTE; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TPMT GENE;

EID: 2942616465     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.23.2869     Document Type: Note

References (28)

1. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP, Ridker PM. A pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004; 291:2821-2827.
2. Gandhi TK, Weingart SN, BorusJ, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348:1556-1564.
3. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277:301-306.
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200-1205.
5. Bates DW, Spell N, Cullen DJ, et al. The cost of adverse drug events in hospitalized patients. JAMA. 1997;277:307-311.
6. Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J. 1998;12:1209-1218.
7. Mackenzie IS, Brown MJ. Genetic profiling versus drug rotation in the optimisation of antihypertensive treatment. Clin Med. 2002;2:465-473.
8. Regaldo A. Inventing the pharmacogenomics business. Am J Health Syst Pharm. 1999;56:40-50.
9. Lindpainter K. Pharmacogenetics and pharmacogenomics in drug discovery and development: an overview. Clin Chem Lab Med. 2003;41:398-410.
10. Oscarson M. Pharmacogenetics of drug metabolizing enzymes: importance for personalized medicine. Clin Chem Lab Med. 2003;41:573-580.
11. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-549.
12. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res. 1999; 16:342-349.
13. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine metabolism. Drug Metab Dispos. 2001;29:601-605.
14. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A. 1995;92:949-953.
15. Szumlanski C, Ottemess D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 1996;15:17-30.
16. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharm Ther. 1997; 62:60-73.
17. Relling MV, Hancock HL, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001-2008.
18. Balis FM, Adamson PC. Application of pharmacogenetics to optimization of mercaptopurine dosing. J Natl Cancer Inst. 1999;91:1983-1984.
19. Lennard L, Lilleyman JS. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monit. 1996;18:328-334.
20. Prescribing information for Tabloid (thioguanine) tablets. Available at: http://www.fda.gov/medwatch/SAFETY/2003/03DEC_PI/Tabloid_PI.pdf. Accessed May 9, 2004.
21. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003; 290:1624-1632.
22. Khoury MJ, Yang Q, Gwinn M, Little J, Flanders WD. An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions. Genet Med. 2004;6:38-47.
23. Computer Retrieval of Information on Scientific Projects. Available at: http://crisp.cit.nih.gov/. Accessed May 3, 2004.
24. National Institute of General Medical Sciences. Pharmacogenetics Research Network. Available at: http://www.nigms.nih.gov/pharmacogenetics/. Accessed May 3, 2004.
25. National Institutes of Health. NIH Roadmap: Accelerating Medical Discovery to Improve Health. Available at: http://www.nihroadmap.nih.gov/. Accessed January 26, 2004.
26. Children's Oncology Group Web site. Available at: http://www .childrensoncologygroup.org/. Accessed November 20, 2003.
27. Fry RN, Avey SG, Sullivan SD. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard - a Foundation of Managed Care Pharmacy Task Force Report. Value Health. 2003;6:505-521.
28. US Food and Drug Administration. Guidance for Industry: Pharmacogenomics Data Submissions. Available at: http://www.fda.gov/cder/guidance/5900dft.doc. Accessed November 3, 2003.